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1  | INTRODUC TION
The direct oral anticoagulants (DOACs) are a relatively new class of 
drugs prescribed in patients with or at risk for venous thromboem-
bolism (VTE) or atrial fibrillation. Historically, anticoagulation of VTE 
patients was based on heparin, heparin derivatives, or oral vitamin 
K antagonists. These historic anticoagulant choices are associated 
with limitations or inconveniences such as the need for infusion (un-
fractionated heparin, UFH) or subcutaneous injection (low molecular 
weight heparin, LMWH), dietary influences (warfarin), and frequent 
or episodic monitoring for potential dose adjustment. These nui-
sances are somewhat mitigated with DOACs, as these orally admin-
istered drugs require no routine or episodic monitoring.1-8 Recent 
clinical publications, however, would suggest that laboratory drug 
measurements may be warranted in certain populations, such as in 
the elderly, those at extremes of body weight, those requiring drugs 
that impact certain metabolic pathways, and those with renal im-
pairment or poor responders.1-9 Moreover, DOAC-treated patients 
that require acute intervention or in emergent situations, such as 
bleeding, acute stroke, trauma, surgery, may require assessment 
of their coagulation status to assure appropriate management.10-13 
Moreover, shortly after their approval status in the United States 
and Europe (dabigatran etexilate in 2010), it became readily apparent 
that the effect of these drugs on laboratory testing, specifically co-
agulation assays (eg, prothrombin time and other assays), was widely 
variable depending on drug type, reagent used, and test applied.
As the prescribing of DOACs has increased, so has our knowl-
edge of this class of anticoagulants on coagulation assays. The initial 
published data, usually made available by pharmaceutical scientists, 
offered somewhat limited information to clinical laboratories as 
either the published testing methods used were not widely avail-
able (eg, ecarin clotting time) or were modified assays (eg, raw or 
drug-calibrated anti-Xa) or a single reagent was used for analysis (eg, 
Neoplastine prothrombin reagent from Diagnostica Stago). In addi-
tion, early knowledge about DOACs and their impact on coagula-
tion assays was often misconstrued and thus guidance documents 
for both clinicians and laboratory professionals generated have since 
been either refuted or refined. The purpose of this document is to 
align our current knowledge on the assessment and impact of DOAC 
anticoagulation in the laboratory. Whether DOAC patients should 
be monitored or episodically measured is beyond the scope of this 
document and will not be addressed.
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The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabi-
gatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, 
all direct anti-Xa inhibitors, have been approved, including rivaroxaban, apixaban, 
edoxaban and betrixaban. Our knowledge about the effect of DOACs on laboratory 
testing, as well as the use of the laboratory for measuring DOACs has been an evolv-
ing process. These drugs are not routinely monitored in the same fashion as couma-
din, but there is an increasing demand on the laboratory to have the capacity to 
adequately assess DOAC anticoagulant effect (pharmacodynamics) or levels (phar-
macokinetics) in either emergent or the routine situations. This manuscript provides 
an update on laboratory guidance and progress of methods for measuring DOACs.
K E Y W O R D S
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1.1 | Direct oral anticoagulants—the currently 
approved drugs
Direct oral anticoagulants are approved (albeit may be regionally lim-
ited) for stroke prevention in nonvalvular atrial fibrillation (NVAF), 
treatment of VTE, secondary prevention of VTE, and/or thrombo-
prophylaxis after knee/hip surgery.1-14 (Table 1) Dose may differ for 
each DOAC and indications, and readers are encouraged to seek 
other sources for peak and tough levels for all DOAC indications.
2  | DOAC L ABOR ATORY INTERFERENCE
Direct oral anticoagulants function as anticoagulants by inhibit-
ing activated serine proteases, specifically thrombin and activated 
factor X (FXa), and for this reason, these drugs affect commonly 
used global coagulation assays as well as select special coagulation 
assays.15-18 Different aPTT and PT reagents show varying respon-
siveness to each of these agents.19 The sensitivity toward anti-IIa 
or anti-Xa agents is activator, phospholipids, and buffer depend-
ent in such a manner that the conditions in which the enzymatic 
assays are performed interfere with the potency of inhibition of 
the DOAC.20 In general, direct thrombin inhibitors (dTI) tend to 
prolong the APTT more than the PT while direct FXa inhibitors 
(DXa) drugs prolong the PT to a greater extent than the aPTT. 
Likewise, one-stage factor activity and inhibitor (ie, Bethesda) as-
says that are dependent on either the aPTT or PT are affected 
by DOAC presence and the degree of interference depends on 
reagent responsiveness, specific DOAC present, and DOAC con-
centration.15-17,21-23 DOAC-affected one-stage factor activity re-
sults spuriously underestimate factor activity which may or may 
not demonstrate nonparallelism. Furthermore, false-positive in-
hibitor titers based on one-stage aPTT or PT factor assays may be 
reported. Chromogenic factor activity assays based on FXa gen-
eration (ie, factor VIII, IX, and X assays) may be underestimated in 
the presence of direct Xa inhibitors, but direct thrombin inhibitors 
have no effect on these assays. Chromogenic FXIII activity will be 
underestimated in the presence of dabigatran.
Thrombin time assays are exquisitely sensitive to the presence 
of dabigatran such that prolongation may be evident even at trough 
levels while DXa agents have no effect on the thrombin time.21 The 
effect of dabigatran on functional fibrinogen measurements is very 
method dependent although most fibrinogen assays are not affected 
by any of the DOACS.24
Thrombophilia testing may be significantly affected by even 
small amounts of DOACS, the effect of which are drug, concen-
tration, test methodologic, and reagent dependent. (Table 2) Tests 
used to screen and confirm the presence of a lupus anticoagulant 
that are based on the aPTT or Russell viper venom (RVV) based may 
be variably affected by the presence of any DOAC, leading to falsely 
elevated or positive results. aPTT-based methods are generally af-
fected more by dabigatran than dXa agents while both classes of 
DOACS impact RVV-based assays.
Chromogenic antithrombin activity assays that are based on FXa 
generation are overestimated in the presence of FXa inhibitor drugs 
and assays based on FIIa generation overestimated by dabigatran. 
Clot-based protein C and S assays are overestimated by all DOACS. 
In DOAC-treated patients, chromogenic protein C and free protein S 
antigen assays are recommended due to their lack of DOAC interfer-
ence. Assays for activated protein C resistance are typically overes-
timated in the presence of any DOAC. With certain methodologies, 
such as a prothrombinase-based activated protein C resistance 
(APCr) assay, therapeutic levels of dabigatran can elevate results to 
the extent that an abnormal APCr result is falsely extended into the 
normal range.25,26 The main advantage of noscarin-based or APTT-
based APC resistance assay is that these methods are not influenced 
TA B L E  1   DOAC characteristics1-8,14,16,17









Trade name Pradaxa Eliquis Bevyxxa Savaysa Lixiana Xarelto
Target Bound and free 
thrombin
Bound and free 
factor Xa
Bound and free 
factor Xa
Bound and free 
factor Xa
Bound and free factor Xa
Bioavailability 3%-7% ~50% ~35% ~60% ~80%-100%
Clearance ~80% renal ~55%	fecal ~85%	fecal ~50%	renal ~70%	renal
Protein binding ~35% ~90% ~60% ~55% ~95%
Tmax 1.5-3	h 3-4 h ~3-4 h 1-2 h 2-3 h








12 ng/mL (mean) 19 (10-39) ng/mL 
(median; IQR)
32 (6-239) ng/mL (mean; 
10th-90th percentile)
aHalf-life is dependent on renal function, with increased half-live associated with renal impairment 
bValues listed for doses associated with prevention and recurrence of deep vein thrombosis and pulmonary embolism. 
cFor betrixaban, values are based on 80 mg once-daily dose for thromboprophylaxis in adult hospitalized patients. 
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by dXa agents. RVV-based APCr assays are influenced by both dTI 
and dXa agents.
With the exception of apixaban, even DOAC trough levels may 
have significant impact on thrombophilia testing. Therefore, to ob-
tain accurate results, whenever possible, hemostasis testing should 
be	performed	4-5	days	after	DOAC	treatment	 is	discontinued,	but	
this is not a recommended clinical point of view. Switching from a 
DOAC to low molecular weight heparin for a transient period of time 
may be an alternative when testing must be completed. If optimum 
patient care requires testing is performed while patients are on 
DOAC therapy, results must be interpreted with caution. However, 
possibilities to avoid this interference are now possible with the 
coming of adsorbent agents able to remove DOAC from the plasma 
sample (see game changers section).
3  | L ABOR ATORY GUIDANCE—MY THS 
AND FAC TS
Tripodi, in a 2016 publication, described various pros and cons as to 
whether or not to measure DOACs.12 This was followed by another 
article Tripodi published in April 2018 which essentially disputed 
previously published notions as to why laboratories do not perform 
DOAC testing such as: test availability, rapid result turn-around-time 
(TAT), difficulty in test performance and interpretation, result vari-
ability, lack of cutoff values, poor definition of tests, and finally the 
fact that conventional tests (eg, PT and APTT) have been recom-
mended to be an acceptable means for assessing DOACs.12 Not re-
lated to the Tripodi paper are additional confounders (in the United 
States) which include a lack of FDA approved methods for quantify-
ing DOACs, and a general reluctance to provide tests that may be 
infrequently used.
Three articles published in 2018 provided guidance directed 
to either laboratories or clinicians regarding laboratory measure-
ment of DOACs.11,16,27 On behalf of the International Council for 
Standardization in Haematology (ICSH), a document was published 
in 2018 to provide laboratory guidance for assessing DOACs.16 Prior 
to manuscript publication, this document was shared with pharma-
ceutical and in vitro diagnostic companies for their comments and 
input. This open-access document provides recommendations ad-
dressing the preanalytical (and general patient and laboratory rec-
ommendations), analytical and postanalytical phases of coagulation 
testing in patients on DOACs. (Table 3) The anti-FXa DOAC betrix-
aban was approved just prior to manuscript submission. Subsequent 
publication about the effect of betrixaban on coagulation testing 
was published in 2018.23 As expected, and consistent with other 
DOACs, there is a wide degree of variability on betrixaban concen-
tration and global assay responsiveness.
The ICSH recommendations for the preanalytical phase include 
nonemergent trough blood collection if routine DOAC assessment 
is desired. The optimal sample for DOAC measurement is collected 
in 3.2% sodium citrate (alternative material acceptable for tandem 
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stability dependent on the DOAC, test, and storage container and 
temperature. The analytical recommendations include the limited 
use of screening assays such as the prothrombin time (PT) and ac-
tivated partial thromboplastin time (APTT), while recognizing the 
use for other assays such as the thrombin time and heparin-related 
anti-Xa assays that may provide some assessment to the presence 
of DOACs with the DOAC result to be reported in ng/mL. Other 
analytical recommendations include assigning tandem mass spec-
trometry as the gold standard for DOAC quantitation, reporting of 
active DOAC metabolites, and the use of drug-calibrated tests (eg, 
ecarin clotting time, ecarin chromogenic assay, dilute thrombin time, 
DOAC calibrated anti-FXa) are suitable as alternative, rapid meth-
ods to tandem mass spectrometry measurements. The guidance 
document recommends the steps required for method validation or 
verification of performance depending on whether the assay is an 
LDT or approved commercial product, respectively. Lastly, the ICSH 
committee recommended that external quality assurance (EQA) 
have two dispatches per year, with at least two samples per dispatch.
While the ICSH document provides guidance for the laboratory, 
there are some limitations, as the changes in the DOAC arena have 
frequently and rapidly, including laboratory methods for DOAC 
measurements, including point-of-care methods, novel methods, or 
modified global assays. The ICSH DOAC committee plans these is-
sues in a short communication in 2019.
Douxfils and colleagues published their recommendations on 
DOAC measurements directed for clinicians.11 However, there are 
salient points that clearly are targeted for the clinical laboratory. 
Included are the capacity for DOAC testing (coagulation analyzers 
ability to perform a particular test or method), and the requirement 
for interpreting the results correctly. Previously, we noted that as 
the expertise lies within the laboratory for laboratory testing, so 
should the interpretation of laboratory results in patients receiving 
DOAC therapy.15,18
Tripodi and colleagues published recommendations from various 
Italian clinical and laboratory societies.27 The key features of these 
recommendations are (a) “Undetectable anti-FXa activity probably 
excludes clinically relevant drug concentrations,” (b) “dedicated tests 
for DOAC should be urgently set up in all clinical laboratories and 
made available to clinicians,” and (c) “…it is useful to measure DOAC 
not only before, but also after administration of the antidotes.”27
Reversal strategies that are specific (Idarucizumab, Praxbind, 
Boehringer Ingelheim for dabigatran and andexanet alpha, AndexXa 
Portola for rivaroxaban and apixaban) or nonspecific (three or four 
factor, activated or nonactivated prothrombin complex concentrates, 
TA B L E  3   ICSH Laboratory Measurements of DOAC recommendations16
Recommendations
General patient Trough drug level assessment for nonemergent situations, with results reported in ng/mL.
Each reported DOAC has accompanying comment with expected trough levels based on published studies.
General laboratory Internal quality control (IQC) performed at least once daily during testing performance.
Sample 3.2% sodium citrate preferred sample for coagulation studies, to be processed within 4 h of collection. Plasma or serum 
can be used for liquid chromatography-mass spectrometry/mass spectrometry.
Plasma samples for dabigatran not tested within 24 h of collection, and samples for anti-Xa DOACs not tested within 8 h 
of collection should be frozen. Frozen plasma can undergo three freeze–thaw cycles.
For thrombin time testing (dabigatran), plasma samples are stable for 4 h at room temperature.
Screening test The PT and/or APTT not reliable measurements of DOAC, especially apixaban, and should not be used to quantify DOAC 
concentrations.
In a patient with known DOAC exposure, a prolonged PT or APTT should be considered secondary to drug effect until 
proven otherwise.
A normal TT excludes the presence of significant dabigatran concentration.
TEG, ROTEM, and other POC not sufficient for assessing DOACs.
Nonspecific POC methods may not have sufficient responsiveness to detect DOAC presence.
Urine screening tests may provide a rapid qualitative and semiquantitative of recent DOAC exposure.
Tandem mass 
spectrometry
LC-MS/MS to be the gold standard test for measuring DOAC concentration, with active metabolites being reported.
Other quantitative 
method
Drug-calibrated DTT, ECA, ECT, and anti-FIIa chromogenic methods are suitable methods to provide quantitation of 
dabigatran.
Drug-calibrated anti-FXa is suitable methods to provide quantitation of anti-Xa DOACs.
Antithrombin supplement anti-FXa methods should not be used for DOAC assessment.
Method 
performance
Prior to test implementation and result reporting, DOAC method validation or verification of performance is required 
requiring a written protocol, to include precision, accuracy, linearity, and other parameters as necessary.
External quality 
assessment
Each laboratory must enroll in a DOAC EQA program, with at least two sample per dispatch, performed at least twice 
annually.
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APCCs or PCCs, respectively) were not fully addressed, as there is 
limited to no published information on those reversal strategies on 
coagulation testing in the setting of specific or nonspecific DOAC 
reversal. Andexanet alpha, an anti-Xa reversal agent for DOAC (ri-
varoxaban and apixaban only in the US) does not require pre- or 
post-treatment assessment of anti-Xa activity as the FDA summary 
report28 indicated “…mean % change in baseline levels did not cor-
relate with hemostatic outcomes.” and thus the FDA is stating that 
no anti-Xa monitoring is required. It is unclear whether the European 
Medicines Agency will also adopt such language. There is currently 
an	open,	phase	3B,	clinical	trial	(NCT02329327)	for	andexanet	alpha	
use in bleeding patients, with anticipated recruitment of ~300 pa-
tients.29 The primary endpoint is no longer a laboratory measure-
ment as noted in ANNEXA-A, ANNEXA-R, and ANNEXA-4 studies, 
but rather a primary outcome demonstrating excellent to good he-
mostasis at 12 hours postadministration (previous outcome measure 
was at 24 hours but was modified in 2018). Perhaps surrogate lab-
oratory measurements will be additionally provided, but not part of 
the clinical trial outcome. Of note, possible interaction of andexanet 
alpha with TFPI has been reported which may tilt the balance to a 
prothrombotic state.
4  | L ABOR ATORY GUIDANCE—THE NEEDS
Laboratories may also require additional guidance on procedures 
that should be followed in situations of bridging or overlapping 
therapy. For example, if a dabigatran-treated patient requires hepa-
rin anticoagulation (eg, with hospital admission), what strategies can 
be used to monitor UFH anticoagulation? Since both dabigatran and 
UFH influence the APTT, patient safety during this bridging period 
requires UFH monitoring other than the traditional APTT. The need 
for alternative testing is also true for the anti-FXa DOACs when 
anti-FXa methods are the primary UFH monitoring tool. For those 
laboratories that may consider implementing a DOAC measuring 
method, the ICSH guidance document provides little detailed infor-
mation about the specifics of testing. As such, an alternative source 
that details cookbook-type instructions for rapid measurements (eg, 
ecarin clotting time, and anti-FXa chromogenic measurements) has 
been published, although not in an open-access format.30
5  | L ABOR ATORY DOAC TESTING: THE 
GAME CHANGERS?
There are several developments in the area DOAC testing that pro-
vide better options for assessing DOACs in acute and nonacute set-
tings. This includes modifications of existing platforms, creation of 
new testing platforms, and alternative collection methods that will 
be discussed below.
DOAC Dipstick (DOASENSE GmbH Heidelberg, Germany): A 
urine dipstick method that can screen and segregate dabigatran from 
anti-Xa DOACs.31 The dipstick also features a creatinine pad to assess 
renal function. Limitations include unreadable pads due to urine color, 
the lack of correlation with plasma DOAC concentrations, and delay 
between drug ingestion and urine detection (1 hour longer to detect 
in urine than in blood). However, the proposed use of these urine dip-
sticks is in acute settings, such as a bleeding patient in the emergency 
department or patient requiring emergent intervention (eg, surgery 
or thrombolysis) with either known or unknown DOAC medication 
history. As urine is readily available, and the read time for this point-
of-care method mere seconds, this may provide rapid assessment of 
a DOAC-treated patient. A postmarket clinical trial32 is currently un-
derway to compare DOAC Dipstick qualitative measurements with 
tandem mass spectrometry DOAC measurements in urine.
Dried blood spot collection for DOAC testing: This method allows 
for at-home blood collection (by fingerstick) that can be scheduled 
at the patient's convenience while still maintaining timed collection 
integrity (recommended trough timed collections).33 The dried blood 
spot sample then can be easily mailed to designated laboratory for 
tandem mass spectrometry measurement. The use of dried blood 
spot collections has been commonly used for decades as a means of 
screening for metabolism disorders in neonates.34
TEG 6S (Haemonetics Corporation, Braintree, MA): The newer 
version of the thromboelastogram (TEG), the TEG 6S uses reso-
nance-frequency microfluidic technology in lieu of the viscoelas-
tic properties of clotting blood using cups and pins.35 The single 
use, four-channel cartridges currently contain kaolin (channel 
1), heparinase (channel 2), tissue factor (channel 3), and abcix-
imab (channel 4). The NOAC assay is a cartridge in development 
replaces heparinase in channel 2 with ecarin and replaces tissue 
factor in channel 3 with factor Xa. The use of ecarin and factor Xa 
will allow specificity when assessing dabigatran and antifactor Xa 
drugs, respectively. In the study evaluating patients on dabigatran, 
rivaroxaban, and apixaban, the ROC analysis yielded a sensitivity 
of 92% and 94% for anti-Xa DOAC and dabigatran, respectively.35 
The TEG 6S provided germane results (clotting time, R) within 
5	minutes	of	test	initiation.
DOAC-Stop: (Haematex Research, Hornsby NSW, Australia)36-39 
The impact of direct oral anticoagulants (DOACs) on laboratory as-
says used for thrombophilia testing (eg, antithrombin, protein S, pro-
tein C, lupus anticoagulant, and activated protein C resistance) is a 
well-known issue and may cause false-positive and false-negative 
results. Therefore, the correct interpretation of tests that are per-
formed in patients taking DOACs is mandatory to prevent misclas-
sification and the subsequent clinical consequences. DOAC-Stop is 
the first device able to remove DOACs from a plasma sample. There 
is now another device on the market that looks similar (eg, DOAC-
remove which is also an absorbent tablet to put into the plasma)39 or 
other that are not yet marketed but look more convenient for daily 
use (eg, the Hemofilter, which is a filter able to provide a plasma 
free of platelet and DOACs).40 The adsorbent procedure appeared 
to be an effective and simple way to overcome the interference of 
DOAC on coagulation tests and should facilitate the interpretation 
of thrombophilia screening tests in patients taking DOACs. Filters 
appear more convenient for the daily use than the tablets.
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ST Genesia (Diagnostica Stago, Asnières sur Seine Cedex, 
France) is an automated analyzer for thrombin generation testing 
and may be a “game changer” for the assessment of DOAC in the 
future.41 Preliminary observations showed that thrombin gener-
ation testing is affected by all anticoagulant drugs and therefore 
it could be the candidate assay. The test has been found to be 
sensitive to all kind of anticoagulants and may best represent 
interindividual response more so than exploring merely plasma 
drug concentrations. In addition to providing the interindividual 
response to an antithrombotic drug, thrombin generation testing 
is also able to explore in more detail the impact of anticoagulants 
on the coagulation process.
6  | CONCLUSION
Following the introduction of DOACs, there has been an evolu-
tion of published information regarding the need and methods 
to measure their concentration in the laboratory as well as their 
impact on coagulation assays including methods to block this in-
terference. This document serves to align our current knowledge 
on the assessment and impact of DOAC anticoagulation in the 
laboratory.
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